1
|
GLOBOCAN 2012 Estimated Cancer Incidence,
Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxDecember
12–2015.
|
2
|
Selcuk H, Kanbay M, Korkmaz M, Gur G,
Akcay A, Arslan H, Ozdemir N, Yilmaz U and Boyacioglu S:
Distribution of HCV genotypes in patients with end-stage renal
disease according to type of dialysis treatment. Dig Dis Sci.
51:1420–1425. 2006. View Article : Google Scholar : PubMed/NCBI
|
3
|
Etik D Ozer, Ocal S and Boyacioglu AS:
Hepatitis C infection in hemodialysis patients: A review. World J
Hepatol. 7:885–895. 2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
O'Toole SM, Fan SL, Yaqoob MM and
Chowdhury TA: Managing diabetes in dialysis patients. Postgrad Med
J. 88:160–166. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Renehen A, Smith U and Kirkman MS: Linking
diabetes and cancer: A consensus on complexity. Lancet.
375:2201–2202. 2010. View Article : Google Scholar : PubMed/NCBI
|
6
|
Arii S, Yamaoka Y, Futagawa S, Inoue K,
Kobayashi K, Kojiro M, Makuuchi M, Nakamura Y, Okita K and Yamada
R: Results of surgical and nonsurgical treatment for small-sized
hepatocellular carcinomas: A retrospective and nationwide survey in
Japan. The Liver Cancer Study Group of Japan. Hepatology.
32:1224–1229. 2000. View Article : Google Scholar : PubMed/NCBI
|
7
|
Ikai I, Itai Y, Okita K, Omata M, Kojiro
M, Kobayashi K, Nakanuma Y, Futagawa S, Makuuchi M and Yamaoka Y:
Report of the 15th follow-up survey of primary liver cancer.
Hepatol Res. 28:21–29. 2004. View Article : Google Scholar : PubMed/NCBI
|
8
|
Shiina S, Teratani T, Obi S, Sato S,
Tateishi R, Fujishima T, Ishikawa T, Koike Y, Yoshida H, Kawabe T
and Omata M: A randomized controlled trial of radiofrequency
ablation with ethanol injection for small hepatocellular carcinoma.
Gastroenterology. 129:122–130. 2005. View Article : Google Scholar : PubMed/NCBI
|
9
|
Hiraoka A, Michitaka K, Horiike N, Hidaka
S, Uehara T, Ichikawa S, Hasebe A, Miyamoto Y, Ninomiya T, Sogabe
I, et al: Radiofrequency ablation therapy for hepatocellular
carcinoma in elderly patients. J Gastroenterol Hepatol. 25:403–407.
2010. View Article : Google Scholar : PubMed/NCBI
|
10
|
Mazzaferro V, Llovet JM, Miceli R, Bhoori
S, Schiavo M, Mariani L, Camerini T, Roayaie S, Schwartz ME, Grazi
GL, et al: Predicting survival after liver transplantation in
patients with hepatocellular carcinoma beyond the Milan criteria: A
retrospective, exploratory analysis. Lancet Oncol. 10:35–43. 2009.
View Article : Google Scholar : PubMed/NCBI
|
11
|
D'Amico F, Schwartz M, Vitale A, Tabrizian
P, Roayaie S, Thung S, Mdel Rio, Martin Guido J, Schiano T and
Cillo U: Predicting recurrence after liver transplantation in
patients with hepatocellular carcinoma exceeding the up-to-seven
criteria. Liver Transpl. 15:1278–1287. 2009. View Article : Google Scholar : PubMed/NCBI
|
12
|
Bruix J and M; Practice Guidelines
Committee, American Association for the Study of Liver Diseases
Sherman: Management of hepatocellular carcinoma. Hepatology.
42:1208–1236. 2005. View Article : Google Scholar : PubMed/NCBI
|
13
|
Hiraoka A, Hiasa Y, Onji M and Michitaka
K: New contrast enhanced ultrasonography agent: Impact of Sonazoid
on radiofrequency ablation. J Gastroenterol Hepatol. 26:616–618.
2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumors. 7th edition. John Wiley
& Sons, Inc.; Hoboken, NJ: 2009
|
15
|
Liver Cancer Study Group of Japan, .
General Rules for the Clinical and Pathological Study of Primary
Liver Cancer. 5th edition. Kanehara & Co., Ltd.; Tokyo: pp.
242009
|
16
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Matsui O, Kadoya M, Yoshikawa J, Gabata T,
Takashima T and Demachi H: Subsegmental transcatheter arterial
embolization for small hepatocellular carcinomas: Local therapeutic
effect and 5-year survival rate. Cancer Chemother Pharmacol. 33
Suppl:S84–S88. 1994. View Article : Google Scholar : PubMed/NCBI
|
18
|
Kudo M, Chung H and Osaki Y: Prognostic
scoring system for hepatocellular carcinoma (CLIP score): Its value
and limitations, and a proposal for a new staging system, the Japan
Integrated Staging Score (JIS score). J Gastroenterol. 38:207–215.
2003. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sakai Y, Izumi N, Tazawa J, Uchihara M,
Akiba T, Marumo F and Sato C: Characteristics of anti-HCV
antibody-positive patients with hepatocellular carcinoma on chronic
hemodialysis: Recommendation of periodic ultrasonography for early
detection. Nephron. 74:386–389. 1996. View Article : Google Scholar : PubMed/NCBI
|
20
|
Henderson WA, Shankar R, Gill JM, Kim KH,
Ghany MG, Skanderson M and Butt AA: Hepatitis C progressing to
hepatocellular carcinoma: The HCV dialysis patient in dilemma. J
Viral Hepat. 17:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
El-Serag HB, Tran T and Everhart JE:
Diabetes increases the risk of chronic liver disease and
hepatocellular carcinoma. Gastroenterology. 126:460–468. 2004.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Noto H, Osame K, Sasazaki T and Noda M:
Substantially increased risk of cancers in patients with diabetes
mellitus: A systematic review and meta-analysis of epidemiologic
evidence in Japan. J Diabetes Complications. 24:345–353. 2010.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Hiraoka A, Ochi M, Matsuda R, Aibiki T,
Okudaira T, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, et
al: Ultrasonography screening for hepatocellular carcinoma in
Japanese patients with diabetes mellitus. J Diabetes. Sep
8–2015.(Epub ahead of print). PubMed/NCBI
|
24
|
Suda G, Kudo M, Nagasaka A, Furuya K,
Yamamoto Y, Kobayashi T, Shinada K, Tateyama M, Konno J, Tsukuda Y,
et al: Efficacy and safety of daclatasvir and asunaprevir
combination therapy in chronic hemodialysis patients with chronic
hepatitis C. J Gastroenterol. Jan 14–2016.(Epub ahead of print).
View Article : Google Scholar
|
25
|
Toyoda H, Kumada T, Tada T, Takaguchi K,
Ishikawa T, Tsuji K, Zeniya M, Iio E and Tanaka Y: Safety and
efficacy of dual direct-acting antiviral therapy (daclatasvir and
asunaprevir) for chronic hepatitis C virus genotype 1 infection in
patients on hemodialysis. J Gastroenterol. Feb 12–2016.(Epub ahead
of print). View Article : Google Scholar
|
26
|
Ikai I, Arii S, Kojiro M, Ichida T,
Makuuchi M, Matsuyama Y, Nakanuma Y, Okita K, Omata M, Takayasu K
and Yamaoka Y: Reevaluation of prognostic factors for survival
after liver resection in patients with hepatocellular carcinoma in
a Japanese nationwide survey. Cancer. 101:796–802. 2004. View Article : Google Scholar : PubMed/NCBI
|
27
|
Hiraoka A, Horiike N, Yamashita Y, Koizumi
Y, Doi K, Yamamoto Y, Hasebe A, Ichikawa S, Yano M, Miyamoto Y, et
al: Efficacy of radiofrequency ablation therapy compared to
surgical resection in 164 patients in Japan with single
hepatocellular carcinoma smaller than 3 cm, along with report of
complications. Hepatogastroenterology. 55:2171–2174.
2008.PubMed/NCBI
|
28
|
Tung CF, Yang DY, Hu WH, Peng YC, Chow WK
and Chen GH: Characteristics of hepatocellular carcinoma in
hemodialysis patients in hepatitis B endemic area.
Hepatogastroenterology. 50:1564–1568. 2003.PubMed/NCBI
|
29
|
Yamagata M, Kanematsu T, Matsumata T,
Nishizaki T, Utsunomiya T, Sugimachi K and Okuda S: Possibility of
hepatic resection in patients on maintenance hemodialysis.
Hepatogastroenterology. 40:249–252. 1993.PubMed/NCBI
|
30
|
Orii T, Takayama T, Haga I, Fukumori T and
Amada N: Efficacy of a liver resection for hepatocellular carcinoma
in patients with chronic renal failure. Surg Today. 38:329–334.
2008. View Article : Google Scholar : PubMed/NCBI
|
31
|
Yeh CC, Lin JT, Jeng LB, et al: Hepatic
resection for hepatocellular carcinoma patients on hemodialysis for
uremia: A nationwide cohort study. World J Surg. 37:2402–2409.
2013. View Article : Google Scholar : PubMed/NCBI
|
32
|
Lee YH, Hsu CY, Hsia CY, et al:
Hepatocellular carcinoma in uremic patients: Is there evidence for
an increased risk of mortality? J Gastroenterol Hepatol.
28:348–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kaw D and Malhotra D: Platelet dysfunction
and end-stage renal disease. Semin Dial. 19:317–322. 2006.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Sarnak MJ and Jaber BL: Mortality caused
by sepsis in patients with end-stage renal disease compared with
the general population. Kidney Int. 58:1758–1764. 2000. View Article : Google Scholar : PubMed/NCBI
|
35
|
Ahonen J and Salmela K: Wound healing and
infections in chronic renal failureSurgery in Renal Failure. Eigler
FW and Jakubowski HD: George Thieme Verlag; New York: pp.
681984
|
36
|
Minami Y, Hayaishi S and Kudo M:
Radiofrequency ablation for hepatic malignancies: Is needle tract
cauterization necessary for preventing iatrogenic bleeding? Dig
Dis. 31:480–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Kondo Y, Yoshida H, Tomizawa Y, Tateishi
R, Shiina S, Tagawa K and Omata M: Percutaneous radiofrequency
ablation of hepatocellular carcinoma in 14 patients undergoing
regular hemodialysis for end-stage renal disease. AJR Am J
Roentgenol. 193:964–969. 2009. View Article : Google Scholar : PubMed/NCBI
|
38
|
Hiraoka A, Ichiryu M, Tazuya N, Ochi H,
Tanabe A, Nakahara H, Hidaka S, Uehara T, Ichikawa S, Hasebe A, et
al: Clinical translation in the treatment of hepatocellular
carcinoma following the introduction of contrast-enhanced
ultrasonography with Sonazoid. Oncol Lett. 1:57–61. 2010.PubMed/NCBI
|